Abstract

BackgroundMethylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Aberrant promoter methylation is considered a hallmark of cancer involved in silencing of tumor suppressor genes and activation of oncogenes. However, recent studies have also challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive.ResultsUsing a large dataset of 672 matched cancerous and healthy methylomes, gene expression, and copy number profiles accross 3 types of tissues from The Cancer Genome Atlas (TCGA), we perform a detailed meta-analysis to clarify the interplay between promoter methylation and gene expression in normal and cancer samples. On the one hand, we recover the existence of a CpG island methylator phenotype (CIMP) with prognostic value in a subset of breast, colon and lung cancer samples, where a common subset of promoter CGIs hypomethylated in normal samples become hypermethylated. However, this hypermethylation is not accompanied by a decrease in expression of the corresponding genes, which are already lowly expressed in the normal genes. On the other hand, we identify tissue-specific sets of genes, different between normal and cancer samples, whose inter-individual variation in expression is significantly correlated with the variation in methylation of the 3’ flanking regions of the promoter CGIs. These subsets of genes are not the same in the different tissues, nor between normal and cancerous samples, but transcription factors are over-represented in all subsets.ConclusionOur results suggest that epigenetic reprogramming in cancer does not contribute to cancer development via direct inhibition of gene expression through promoter hypermethylation. It may instead modify how the expression of a few specific genes, particularly transcription factors, are associated with DNA methylation variations in a tissue-dependent manner.Electronic supplementary materialThe online version of this article (doi:10.1186/s12864-015-1994-2) contains supplementary material, which is available to authorized users.

Highlights

  • Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation

  • Classification of genes based on their CGI methylation profiles in normal and cancerous tissues We first assess how promoter methylation profiles differ between genes, when for each gene we consider the average methylation profile across normal or cancerous samples

  • We restrict our analysis to the 1827 CGI+SS where at least 20 CpG probes are measured by the technology in order to have high enough coverage to measure the methylation variation within each CGI+SS

Read more

Summary

Introduction

Methylation of high-density CpG regions known as CpG Islands (CGIs) has been widely described as a mechanism associated with gene expression regulation. Recent studies have challenged the simple model of gene expression control by promoter methylation in cancer, and the precise mechanism of and role played by changes in DNA methylation in carcinogenesis remains elusive. DNA methylation is one of the main epigenetic mechanisms, alongside histone modifications, that plays a significant role in gene silencing [1], tissue differentiation [2], cellular development [3], X-chromosome inactivation [4], or genetic imprinting [5]. Aberrant hyper-methylation of high-density CpG regions known as CpG Islands (CGIs) [6] and genome-wide hypo-methylation [7] have. Reddington et al speculate that epigenetic reprogramming might lead to an altered Polycomb binding landscape which could impact genome regulation [24]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call